The Hospital Universitario Ramón y Cajal is a public general hospital located in the Valverde neighborhood, in Madrid, Spain, part of the hospital network of the Servicio Madrileño de Salud. It is one of the healthcare institutions associated to the University of Alcalá for the purpose of clinical internship.

There are 901 beds in Hospital Universitario Ramon y Cajal.

During the past decade, Hospital Universitario Ramon y Cajal conducted 798 clinical trials. In the 10-year time frame, 798 clinical trials started and 243 clinical trials were completed, i.e. on average, 30.5% percent of trials that started reached the finish line to date. In the past 5 years, 396 clinical trials started and 186 clinical trials were completed. i.e. 47% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Hospital Universitario Ramon y Cajal" #1 sponsor was "Pfizer" with 47 trials, followed by "PETHEMA Foundation" with 44 trials sponsored, "Janssen Research & Development, LLC" with 34 trials sponsored, "Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal" with 32 trials sponsored and "Gilead Sciences" with 32 trials sponsored. Other sponsors include 892 different institutions and companies that sponsored additional 420 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Hospital Universitario Ramon y Cajal" #1 collaborator was "Merck Sharp & Dohme LLC" with 25 trials as a collaborator, "Pfizer" with 19 trials as a collaborator, "Apices Soluciones S.L." with 18 trials as a collaborator, "AstraZeneca" with 17 trials as a collaborator and "Bristol-Myers Squibb" with 16 trials as a collaborator. Other collaborators include 710 different institutions and companies that were collaborators in the rest 478 trials.

According to Clinical.Site data, the most researched conditions in "Hospital Universitario Ramon y Cajal" are "Breast Cancer" (51 trials), "Multiple Myeloma" (28 trials), "HIV Infections" (22 trials), "Atrial Fibrillation" (16 trials) and "COVID-19" (15 trials). Many other conditions were trialed in "Hospital Universitario Ramon y Cajal" in a lesser frequency.

Most popular intervention types in "Hospital Universitario Ramon y Cajal" are "Drug" (813 trials), "Other" (110 trials), "Device" (69 trials), "Biological" (53 trials) and "Procedure" (45 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (156 trials), "Paclitaxel" (20 trials), "Carboplatin" (19 trials), "Dexamethasone" (18 trials) and "Gemcitabine" (18 trials). Other intervention names were less common.

The vast majority of trials in "Hospital Universitario Ramon y Cajal" are 965 trials for "All" genders, 80 trials for "Female" genders and 39 trials for "Male" genders.

Currently, there are 412 active trials in "Hospital Universitario Ramon y Cajal". 5 are not yet recruiting, 241 are recruiting, 163 are Active, not recruiting, and 3 are Enrolling by invitation. In total, there were 500 completed trials in Hospital Universitario Ramon y Cajal, 2 suspended trials, and 112 terminated clinical trials to date.

Out of the total trials that were conducted in Hospital Universitario Ramon y Cajal, 113 "Phase 1" clinical trials were conducted, 348 "Phase 2" clinical trials and 372 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 78 trials, and there were also 73 trials that are defined as “Not Applicable".

Hospital Universitario Ramon y Cajal has several departments that took part in Clinical trials: "Hospital Ramon y Cajal; Servicio de Neurologia" - 10 trials, "Hospital Ramon y Cajal; Servicio de Oncologia" - 69 trials, "Hospital Ramon y Cajal; Servicio de Hematologia" - 3 trials, "Hospital Ramon y Cajal ; Servicio de Reumatologia" - 6 trials, "Hospital Ramón y Cajal;Servicio de Neumología" - 2 trials